Results 211 to 220 of about 60,221 (291)

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma. [PDF]

Cancer Immunol Immunother
Lutz J, Feist RK, Sonntag T, Peguero-Sánchez E, Wolter K, Bick R, Bauer J, Walz JS, Heidenreich R.   +8 more
europepmc   +1 more source

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

, 2017
Yong‐Chen Lu, Linda L. Parker, Tangying Lu, Zhili Zheng, Mary Ann Toomey, Donald E. White, Xin Yao, Yong F. Li, Paul F. Robbins, Steven A. Feldman, Pierre van der Bruggen, Christopher A. Klebanoff, Stephanie L. Goff, Richard M. Sherry, Udai S. Kammula, James C. Yang, Steven A. Rosenberg   +16 more
openalex   +2 more sources

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Humoral rejection in heart transplantation in the current era. [PDF]

JHLT Open
Sheridan J, Urschel S.
europepmc   +1 more source

HLA Class II Histocompatibility Antigen, DRB1-4 Beta Chain Protein [PDF]

, 2020
openaire   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy? [PDF]

J Immunother Cancer
van Wandeloo IMB, Bol K, van Herpen C, de Vries IJM, Schreibelt G.   +4 more
europepmc   +1 more source

Cytokine-Induced Major Histocompatibility Complex Class II Antigens on Cultured Bovine Mammary Gland Epithelial Cells

, 1994
John L. Fitzpatrick, Susanne Mayer, Camila Vilela, P W Bland, C.R. Stokes   +4 more
openalex   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source